ストックスクリーナーアプリを入手
8.25
3.62%
-0.31
前日終値:
$8.56
開ける：
$8.5
24時間の取引高:
811.44K
Relative Volume:
0.82
時価総額：
$796.20M
収益：
-
当期純損益:
$-43.16M
株価収益率:
-15.00
EPS:
-0.55
ネットキャッシュフロー:
$-29.31M
1週間 パフォーマンス:
-11.86%
1か月 パフォーマンス:
-5.39%
6か月 パフォーマンス:
-10.71%
1年 パフォーマンス:
+112.63%
1日の値動き範囲:
$8.23
$8.6779
1週間の範囲:
$8.20
$9.48
52週間の値動き範囲:
$3.51
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
名前
Anavex Life Sciences Corporation
セクター
電話
844-689-3939
住所
630 5TH AVENUE, NEW YORK
AVXL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
8.25 | 796.20M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-09-23 | 開始されました | BTIG Research | Buy |
| 2020-12-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-28 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-02-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 開始されました | Janney | Buy |
| 2018-05-16 | 再開されました | Maxim Group | Buy |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-02-07 | 開始されました | Noble Financial | Buy |
| 2016-03-29 | 開始されました | FBR Capital | Outperform |
すべてを表示
Anavex Life Sciences Corporation (AVXL) 最新ニュース
Anavex Life Sciences Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times
Anavex Life Sciences Corp. to Announce Second Fiscal Quarter Financial Results on May 13, 2025 - Nasdaq
Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World
Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com
Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus
Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan
Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. to Present at The Citizens Life Sciences Conference in New York, May 2025 - Nasdaq
Press Release Distribution & PR Platform - ACCESS Newswire
Anavex Life Sciences Corporation’s Market Journey: Closing Strong at 9.31, Up 1.09 - DWinneX
Buying Buzz: Anavex Life Sciences Corporation [AVXL] Director Donhauser Peter D.O. purchases 2,835 shares of the company – Knox Daily - knoxdaily.com
AVXL overperforms with a 5.14 increase in share price - uspostnews.com
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - The Manila Times
Harvard-Trained Alzheimer's Pioneer With 35,000-Patient Database Strengthens Anavex's Scientific Team - Stock Titan
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer’s Data ... By GuruFocus - Investing.com Canada
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by LPL Financial LLC - Defense World
Anavex Life Sciences Presents Novel Alzheimer Treatment Research at International Conference in Abu Dhabi - Nasdaq
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East - TradingView
Breakthrough Alzheimer's Treatment Shows Novel Mechanism: Key Phase IIb/III Trial Results Unveiled - Stock Titan
Geode Capital Management LLC Has $20.14 Million Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. (NASDAQ:AVXL) Holdings Raised by Alliancebernstein L.P. - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences LawsuitAVXL - ACCESS Newswire
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Wellington Management Group LLP Makes New $1.70 Million Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Raymond James Financial Inc. Acquires Shares of 15,584 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Prudential Financial Inc. Acquires Shares of 10,160 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Vanguard Group Inc. Sells 59,727 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Corebridge Financial Inc. Trims Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Four-Year Data on New Drug for Early AD Positive - streetwisereports.com
Biotech Company Finds High-Impact Alzheimer's Therapy in Europe - streetwisereports.com
Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World
Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years - Benzinga
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease - The Manila Times
Breakthrough: New Alzheimer's Drug Cuts Cognitive Decline Over 4 Years in Clinical Trial - Stock Titan
Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Anavex Life Sciences Corporation (AVXL)May 13, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class ActionAVXL - ACCESS Newswire
AVXL’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Anavex Life Sciences Corporation (AVXL) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):